NeoGenomics, Inc. Revenue from Contract with Customer, Including Assessed Tax
NeoGenomics, Inc. (NEO) reported Revenue from Contract with Customer, Including Assessed Tax of $201.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-07-28
- NeoGenomics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $201.66M, a 11.21% increase year-over-year.
- NeoGenomics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $186.67M, a 11.09% increase year-over-year.
- NeoGenomics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $190.17M, a 10.56% increase year-over-year.
- NeoGenomics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $187.80M, a 11.90% increase year-over-year.
- NeoGenomics, Inc. revenue from contract with customer, including assessed tax for fiscal 2025 was $727.33M, a 10.11% increase from fiscal 2024.
- NeoGenomics, Inc. revenue from contract with customer, including assessed tax for fiscal 2024 was $660.57M, a 11.65% increase from fiscal 2023.
- NeoGenomics, Inc. revenue from contract with customer, including assessed tax for fiscal 2023 was $591.64M, a 16.07% increase from fiscal 2022.
- NeoGenomics, Inc. revenue from contract with customer, including assessed tax for fiscal 2022 was $509.73M, a 5.24% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $201.66M 10-Q · filed 2026-07-28 | $388.33M 10-Q · filed 2026-07-28 | $578.50M derived: sum of 3 quarters · filed 2026-07-28 | $766.29M derived: sum of 4 quarters · filed 2026-07-28 | |
| 2026-03-31 | $186.67M 10-Q · filed 2026-04-28 | $376.84M derived: sum of 2 quarters · filed 2026-04-28 | $564.64M derived: sum of 3 quarters · filed 2026-04-28 | $745.97M derived: sum of 4 quarters · filed 2026-07-28 | |
| 2025-12-31 | $190.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $377.97M derived: sum of 2 quarters · filed 2026-02-17 | $559.30M derived: sum of 3 quarters · filed 2026-07-28 | $727.33M 10-K · filed 2026-02-17 | |
| 2025-09-30 | $187.80M 10-Q · filed 2025-10-28 | $369.13M derived: sum of 2 quarters · filed 2026-07-28 | $537.16M 10-Q · filed 2025-10-28 | $709.16M derived: sum of 4 quarters · filed 2026-07-28 | |
| 2025-06-30 | $181.33M 10-Q · filed 2026-07-28 | $349.37M 10-Q · filed 2026-07-28 | $521.37M derived: sum of 3 quarters · filed 2026-07-28 | $689.19M derived: sum of 4 quarters · filed 2026-07-28 | |
| 2025-03-31 | $168.03M 10-Q · filed 2026-04-28 | $340.04M derived: sum of 2 quarters · filed 2026-04-28 | $507.86M derived: sum of 3 quarters · filed 2026-04-28 | $672.36M derived: sum of 4 quarters · filed 2026-04-28 | |
| 2024-12-31 | $172.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $339.82M derived: sum of 2 quarters · filed 2026-02-17 | $504.33M derived: sum of 3 quarters · filed 2026-02-17 | $660.57M 10-K · filed 2026-02-17 | |
| 2024-09-30 | $167.82M 10-Q · filed 2025-10-28 | $332.33M derived: sum of 2 quarters · filed 2025-10-28 | $488.57M 10-Q · filed 2025-10-28 | $644.12M derived: sum of 4 quarters · filed 2026-02-17 | |
| 2024-06-30 | $164.50M 10-Q · filed 2025-07-29 | $320.74M 10-Q · filed 2025-07-29 | $476.29M derived: sum of 3 quarters · filed 2026-02-17 | $628.25M derived: sum of 4 quarters · filed 2026-02-17 | |
| 2024-03-31 | $156.24M 10-Q · filed 2025-04-29 | $311.79M derived: sum of 2 quarters · filed 2026-02-17 | $463.75M derived: sum of 3 quarters · filed 2026-02-17 | $610.66M derived: sum of 4 quarters · filed 2026-02-17 | |
| 2023-12-31 | $155.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $307.51M derived: sum of 2 quarters · filed 2026-02-17 | $454.42M derived: sum of 3 quarters · filed 2026-02-17 | $591.64M 10-K · filed 2026-02-17 | |
| 2023-09-30 | $151.95M 10-Q · filed 2024-11-05 | $298.87M derived: sum of 2 quarters · filed 2024-11-05 | $436.09M 10-Q · filed 2024-11-05 | $574.80M derived: sum of 4 quarters · filed 2025-02-18 | |
| 2023-06-30 | $146.92M 10-Q · filed 2024-07-30 | $284.14M 10-Q · filed 2024-07-30 | $422.84M derived: sum of 3 quarters · filed 2025-02-18 | $551.62M derived: sum of 4 quarters · filed 2025-02-18 | |
| 2023-03-31 | $137.22M 10-Q · filed 2024-04-30 | $275.93M derived: sum of 2 quarters · filed 2025-02-18 | $404.71M derived: sum of 3 quarters · filed 2025-02-18 | $529.78M derived: sum of 4 quarters · filed 2025-02-18 | |
| 2022-12-31 | $138.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $267.49M derived: sum of 2 quarters · filed 2025-02-18 | $392.56M derived: sum of 3 quarters · filed 2025-02-18 | $509.73M 10-K · filed 2025-02-18 | |
| 2022-09-30 | $128.78M 10-Q · filed 2023-11-06 | $253.85M derived: sum of 2 quarters · filed 2023-11-06 | $371.02M 10-Q · filed 2023-11-06 | $496.75M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2022-06-30 | $125.07M 10-Q · filed 2023-08-08 | $242.24M 10-Q · filed 2023-08-08 | $367.97M derived: sum of 3 quarters · filed 2024-02-20 | $489.31M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2022-03-31 | $117.17M 10-Q · filed 2023-05-09 | $242.90M derived: sum of 2 quarters · filed 2024-02-20 | $364.24M derived: sum of 3 quarters · filed 2024-02-20 | $485.96M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2021-12-31 | $125.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $247.07M derived: sum of 2 quarters · filed 2024-02-20 | $368.80M derived: sum of 3 quarters · filed 2024-02-20 | $484.33M 10-K · filed 2024-02-20 | |
| 2021-09-30 | $121.34M 10-Q · filed 2022-11-08 | $243.06M derived: sum of 2 quarters · filed 2022-11-08 | $358.60M 10-Q · filed 2022-11-08 | $484.59M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-06-30 | $121.72M 10-Q · filed 2022-08-09 | $237.26M 10-Q · filed 2022-08-09 | $363.25M derived: sum of 3 quarters · filed 2023-02-24 | $488.70M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-03-31 | $115.53M 10-Q · filed 2022-05-09 | $241.53M derived: sum of 2 quarters · filed 2023-02-24 | $366.97M derived: sum of 3 quarters · filed 2023-02-24 | $453.95M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2020-12-31 | $126.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $251.44M derived: sum of 2 quarters · filed 2023-02-24 | $338.42M derived: sum of 3 quarters · filed 2023-02-24 | $444.45M 10-K · filed 2023-02-24 | |
| 2020-09-30 | $125.44M 10-Q · filed 2021-11-04 | $212.42M derived: sum of 2 quarters · filed 2021-11-04 | $318.45M 10-Q · filed 2021-11-04 | $425.32M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | $86.98M 10-Q · filed 2021-08-09 | $193.01M 10-Q · filed 2021-08-09 | $299.88M derived: sum of 3 quarters · filed 2021-08-09 | $404.55M derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | $106.03M 10-Q · filed 2021-05-06 | $212.90M derived: sum of 2 quarters · filed 2021-05-06 | $317.57M derived: sum of 3 quarters · filed 2021-05-06 | $419.28M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | $106.87M 10-K · filed 2020-02-28 | $211.54M derived: sum of 2 quarters · filed 2020-10-29 | $313.25M derived: sum of 3 quarters · filed 2020-10-29 | $408.83M 10-K · filed 2022-02-25 | |
| 2019-09-30 | $104.67M 10-Q · filed 2020-10-29 | $206.38M derived: sum of 2 quarters · filed 2020-10-29 | $301.96M 10-Q · filed 2020-10-29 | $378.44M derived: sum of 4 quarters · filed 2020-10-29 | |
| 2019-06-30 | $101.71M 10-Q · filed 2020-07-31 | $197.29M 10-Q · filed 2020-07-31 | $273.76M derived: sum of 3 quarters · filed 2020-07-31 | $342.86M derived: sum of 4 quarters · filed 2020-07-31 | |
| 2019-03-31 | $95.58M 10-Q · filed 2020-04-29 | $172.05M derived: sum of 2 quarters · filed 2020-04-29 | $241.15M derived: sum of 3 quarters · filed 2020-04-29 | $308.89M derived: sum of 4 quarters · filed 2020-04-29 | |
| 2018-12-31 | $76.47M 10-K · filed 2020-02-28 | $145.57M derived: sum of 2 quarters · filed 2020-02-28 | $213.32M derived: sum of 3 quarters · filed 2020-02-28 | $276.74M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $69.10M 10-K · filed 2020-02-28 | $69.10M 10-Q · filed 2018-11-06 | $136.84M derived: sum of 2 quarters · filed 2020-02-28 | $200.27M 10-Q · filed 2019-11-13 | $261.69M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $67.75M 10-K · filed 2020-02-28 | $131.17M 10-Q · filed 2019-08-07 | $192.59M derived: sum of 3 quarters · filed 2020-02-28 | $251.73M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2018-03-31 | $63.42M 10-K · filed 2020-02-28 | $124.84M derived: sum of 2 quarters · filed 2020-02-28 | $183.98M derived: sum of 3 quarters · filed 2020-02-28 | $246.25M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2017-12-31 | $61.42M 10-K · filed 2019-02-26 | $120.56M derived: sum of 2 quarters · filed 2019-02-26 | $182.82M derived: sum of 3 quarters · filed 2019-02-26 | $240.25M 10-K · filed 2020-02-28 | |
| 2017-09-30 | $59.14M 10-K · filed 2019-02-26 | $121.40M derived: sum of 2 quarters · filed 2019-02-26 | $178.83M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $62.26M 10-K · filed 2019-02-26 | $119.69M 10-Q · filed 2018-08-06 | |||
| 2017-03-31 | $57.43M 10-K · filed 2019-02-26 | $57.43M 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | $231.81M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |